BioCryst Pharmaceuticals (BCRX) Stock Forecast & Price Target

BioCryst Pharma is supported by Orladeyo’s continued commercial strength, with 2Q26 revenue of $158M, up 10% year over year and essentially in line with consensus, while total revenue of $218M and non-GAAP operating profit of $113M both exceeded expectations. The company’s outlook is further strengthened by a broader hereditary angioedema franchise, as the pediatric pellet formulation has already generated 47 prescriptions on a YTD basis and navenibart offers a differentiated long-acting Q3M/Q6M dosing profile that could expand the addressable patient base. Fundamental confidence is also reinforced by a competitive yet favorable clinical backdrop, since positive CHAPTER-3 data for deucrictibant appears largely in-line with expectations and does not undermine BioCryst’s positioning as an HAE anchor with multiple pipeline catalysts ahead.

BioCryst Pharma is viewed negatively because its pipeline faces meaningful regulatory and clinical uncertainty, including the possibility that regulators demand additional data, longer studies, or product labels that weaken market traction. The company also appears financially fragile, as it may need additional external funding and could face delays or termination of development programs if it cannot access the capital markets. Commercially, Orladeyo’s growth may slow or lose share, while the outlook for >$1B peak sales or profitability is unclear amid risks that Netherton Syndrome and avoralstat programs fail to show compelling efficacy or benefit/risk.